Chronic Lung Allograft Dysfunction: Clinical Manifestations and Immunologic Mechanisms.
| Autor: | Bery AI; Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO., Belousova N; Pneumology, Adult Cystic Fibrosis Center and Lung Transplantation Department, Foch Hospital, Suresnes, France., Hachem RR; Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah School of Medicine, Salt Lake City, UT., Roux A; Pneumology, Adult Cystic Fibrosis Center and Lung Transplantation Department, Foch Hospital, Suresnes, France.; Paris Transplant Group, INSERM U970s, Paris, France., Kreisel D; Department of Surgery, Washington University School of Medicine, St. Louis, MO.; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Transplantation [Transplantation] 2024 Aug 06. Date of Electronic Publication: 2024 Aug 06. |
| DOI: | 10.1097/TP.0000000000005162 |
| Abstrakt: | The term "chronic lung allograft dysfunction" has emerged to describe the clinical syndrome of progressive, largely irreversible dysfunction of pulmonary allografts. This umbrella term comprises 2 major clinical phenotypes: bronchiolitis obliterans syndrome and restrictive allograft syndrome. Here, we discuss the clinical manifestations, diagnostic challenges, and potential therapeutic avenues to address this major barrier to improved long-term outcomes. In addition, we review the immunologic mechanisms thought to propagate each phenotype of chronic lung allograft dysfunction, discuss the various models used to study this process, describe potential therapeutic targets, and identify key unknowns that must be evaluated by future research strategies. Competing Interests: The authors declare no conflicts of interest. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|